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DEAR EDITOR, Many studies have investigated risk factors for
poor outcomes following COVID-19. These studies are impor-
tant for planning targeted prevention and/or intervention. A
UK cohort study found that a composite variable of autoim-
mune diseases, representing rheumatoid arthritis, lupus or
psoriasis, was associated with an increased risk of death owing
to COVID-19 [hazard ratio 119, 95% confidence interval (CI)
111–127].1 In contrast, a case series of patients with COVID-
19 in two US centres found that atopic eczema (AE) was asso-
ciated with a reduction in the risk of hospitalization in
patients with COVID-19 [odds ratio (OR) 051, 95% CI 025–
090].2 Most published studies investigated the risk of infec-
tion with SARS-CoV-2 and poor COVID-19 outcomes associ-
ated with oral or biological treatment for psoriasis/eczema
rather than for the condition itself.3 Our aim was to investi-
gate the risk of COVID-19 infection associated with having
psoriasis or AE in a UK tertiary dermatology centre [Salford
Royal NHS Foundation Trust (SRFT), Manchester, UK].
We performed a cross-sectional study using data extracted
from the SRFT electronic patient records (EPRs) of inpatient
and outpatient visits. SRFT hosts one of the largest UK derma-
tology departments; a tertiary psoriasis clinic; and one of the
few inpatient dermatology wards in the country. We included
all patients aged ≥ 18 years who had one or more visits to the
SRFT dermatology service between June 2018 and February
2021. Our exposure of interest was an inpatient or outpatient
diagnosis of psoriasis or AE. We excluded all individuals who
did not reside in Salford as they were unlikely to have pre-
sented to SRFT for COVID-19 testing.
Clinical diagnoses were coded using the International Classi-
fication of Diseases, 10th Revision codes for inpatient admis-
sions. Outpatient diagnoses [including comorbidities of
hypertension, chronic obstructive pulmonary disease and dia-
betes mellitus (DM)] were extracted from letters. Data on
immunosuppressive treatments were extracted from letters
when vulnerable adults were identified for targeted protection
measures (‘shielding’), during the COVID-19 pandemic, on
the advice of the UK government in March 2020.4 The most
up-to-date values for age, body mass index (BMI), ethnicity
and sex were extracted from the EPR. Our outcome of interest
was patients who had a positive polymerase chain reaction
SARS-CoV2 swab test. We also identified individuals who were
admitted to hospital for management of COVID-19. The
descriptive data were summarized by median and interquartile
range for continuous data, and by number and percentage for
dichotomous/categorical variables. We fitted logistic regres-
sion models with COVID-19 diagnosis as the outcome and
psoriasis or AE as the exposure, additionally adjusting for
potential confounders (median-centred age, sex, ethnicity,
BMI) and potential mediators between the exposure and the
outcome (hypertension and DM) in separate complete-case
and multiply imputed (MI) (20 sets) models.
Information for 56 835 patients was extracted; 13 162
patients were eligible for inclusion. There were 1427 (108%)
patients with psoriasis and 624 (47%) with AE. In total, 176
(13%) of the eligible patients had COVID-19, 38 (216%) of
whom were hospitalized [two with psoriasis (who recovered),
none with AE]. Baseline demographic data are presented in
Table 1. We did not find a statistically significant elevated risk
for infection with COVID-19 in patients with psoriasis [unad-
justed OR 060 (95% CI 033–108), complete-case adjusted
OR 098 (95% CI 046–208), MI adjusted OR 050 (95% CI
028–092)] or AE [unadjusted OR 071 (95% CI 031–160),
complete-case adjusted OR 060 (95% CI 022–164), MI
adjusted OR 067 (95% CI 029–153)].
A diagnosis of psoriasis or AE was not associated with an
increase in the risk of testing positive for COVID-19 com-
pared with other patients attending the dermatology depart-
ment for other conditions such as skin cancer. One of the
strengths of this study is the inclusion of a generalizable
population of patients with psoriasis and AE, regardless of
treatment. The limitations of this study include potential mis-
classification of confounders (owing to missing information
from letters) and outcome (community COVID-19 test results
were not available), lack of adjustment for potential con-
founders such as smoking, and effect estimate imprecision.
Additionally, patients with inflammatory skin diseases may
practice stricter shielding measures, which could explain the
halving in risk for psoriasis in the MI adjusted analysis. It
has been shown that people with psoriasis receiving targeted
biological and systemic therapies are likely to follow the
most stringent risk-mitigating behaviours.5 In conclusion,
psoriasis and AE were not associated with an increased risk
of testing positive for COVID-19. On this evidence, it
appears that psoriasis and AE should not be considered as
risk factors for contracting COVID-19. Further research in
larger cohorts with representative denominators is needed to
confirm this finding.
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Age, years 550 (360–710) 750 (590–830)
Sex
Male 5464 (421) 88 (500)
Female 7522 (579) 88 (500)
Body mass index 274 (240–316) 283 (249–329)
Missing 7609 (572) 53 (301)
Ethnicity
White 12 157 (936) 173 (983)
Afro-Caribbean 69 (05) 0 (00)
South Asian 154 (12) 3 (17)
Other Asian 144 (11) 0 (00)
Mixed 65 (05) 0 (00)
Other ethnic
groups
159 (12) 0 (00)
Not recorded 238 (18) 0 (00)
Disease exposures
Psoriasis 1415 (109) 12 (68)
Atopic eczema 618 (48) 6 (34)
Hypertension 100 (08) 6 (34)
Chronic obstructive
pulmonary disease
16 (01) 0 (00)




68 (05) 0 (00)
Interleukin 17/23
inhibitor
41 (03) 0 (00)
Prednisolone 20 (02) 0 (00)
Dupilumab 18 (01) 0 (00)
Admission owing
to COVID-19
0 (00) 38 (216)
Continuous data are presented as median and interquartile range;
dichotomous/categorical variables are presented as n (%).
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